Log in to save to my catalogue

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid canc...

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid canc...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3107731

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Chemotherapy has historically proven ineffective in advanced differentiated thyroid cancers, but the realisation that various tyrosine kinases are activated in the disease suggested a potential therapeutic role for tyrosine-kinase inhibitors. We investigated the safety and efficacy of pazopanib. Methods This phase 2 trial was don...

Alternative Titles

Full title

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3107731

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3107731

Other Identifiers

ISSN

1470-2045,1474-5488

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(10)70203-5

How to access this item